Subcutaneous Campath-1H [alemtuzumab] in fludarabine-refractory CLL [chronic lymphocytic leukaemia].
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2013
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2008 Final results presented at the American Society of Hematology annual meeting.
- 24 Jul 2006 New trial record.